Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

We previously showed an association between low vitamin D levels and high opioid doses to alleviate pain in palliative cancer patients.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections: Results from a matched case-control study

Source: Article title.

This is a case-control study where the vitamin D supplemented patients were followed prospectively with regards to their opioid consumption, infections and quality of life.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections: Results from a matched case-control study

Case-control study · PLoS ONE · 2017

Original publication title

Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections: Results from a matched case-control study

Maria Helde-Frankling; Jonas Höijer; Jenny Bergqvist; Linda Björkhem-Bergman

© 2017 Helde-Frankling et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Vitamin D supplementation to palliative cancer patients is safe and improvement in pain management is noted as early as 1 month after treatment. Decreased infections are noted 3 months after vitamin D treatment. The results from this pilot-study have been used for the power-calculation of a future randomized, placebo-controlled, double-blind study called “Palliative-D” that will start in Nov 2017 and will include 254 palliative cancer patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

We previously showed an association between low vitamin D levels and high opioid doses to alleviate pain in palliative cancer patients. The aim of this case-controlled study was to investigate if vitamin D supplementation could improve pain management, quality of life (QoL) and decrease infections in palliative cancer patients.

Source: Background

Abstract: What methods does the paper describe?

Thirty-nine palliative cancer patients with levels of 25-hydroxyvitamin D < 75 nmol/L were supplemented with vitamin D 4000 IE/day, and were compared to 39 untreated, matched “control”-patients from a previous study at the same ward. Opioid doses, antibiotic consumption and QoL-scores measured with the Edmonton Symptom Assessment Scale (ESAS) were monitored. The primary endpoint was the change from baseline after 1 and 3 months compared between the groups using linear regression with adjustment for a potential cofounding factor.

Source: Methods

Abstract: Results

After 1 month the vitamin D treated group had a significantly decreased fentanyl dose compared to the untreated group with a difference of 46 μg/h; 95% CI 24 to 78, which increased further at 3 months to 91 μg/h; 95% CI 56 to 140 μg/h. The ESAS QoL-score improved in the Vitamin D group the first month; -1.4; 95% CI -2.6: (-0.21). The vitamin D-treated group had significantly lower consumption of antibiotics after 3 months compared to the untreated group, the difference was -26%; 95%CI -0.41%: (-0.12%).

Vitamin D was well tolerated by all patients and no adverse events were reported.

Source: Results

Abstract: Conclusion

Vitamin D supplementation to palliative cancer patients is safe and improvement in pain management is noted as early as 1 month after treatment. Decreased infections are noted 3 months after vitamin D treatment. The results from this pilot-study have been used for the power-calculation of a future randomized, placebo-controlled, double-blind study called “Palliative-D” that will start in Nov 2017 and will include 254 palliative cancer patients.

Source: Conclusion
Authors’ abstract

Background

We previously showed an association between low vitamin D levels and high opioid doses to alleviate pain in palliative cancer patients. The aim of this case-controlled study was to investigate if vitamin D supplementation could improve pain management, quality of life (QoL) and decrease infections in palliative cancer patients.

Methods

Thirty-nine palliative cancer patients with levels of 25-hydroxyvitamin D < 75 nmol/L were supplemented with vitamin D 4000 IE/day, and were compared to 39 untreated, matched “control”-patients from a previous study at the same ward. Opioid doses, antibiotic consumption and QoL-scores measured with the Edmonton Symptom Assessment Scale (ESAS) were monitored. The primary endpoint was the change from baseline after 1 and 3 months compared between the groups using linear regression with adjustment for a potential cofounding factor.

Results

After 1 month the vitamin D treated group had a significantly decreased fentanyl dose compared to the untreated group with a difference of 46 μg/h; 95% CI 24 to 78, which increased further at 3 months to 91 μg/h; 95% CI 56 to 140 μg/h. The ESAS QoL-score improved in the Vitamin D group the first month; -1.4; 95% CI -2.6: (-0.21). The vitamin D-treated group had significantly lower consumption of antibiotics after 3 months compared to the untreated group, the difference was -26%; 95%CI -0.41%: (-0.12%).

Vitamin D was well tolerated by all patients and no adverse events were reported.

Conclusion

Vitamin D supplementation to palliative cancer patients is safe and improvement in pain management is noted as early as 1 month after treatment. Decreased infections are noted 3 months after vitamin D treatment. The results from this pilot-study have been used for the power-calculation of a future randomized, placebo-controlled, double-blind study called “Palliative-D” that will start in Nov 2017 and will include 254 palliative cancer patients.

Publication and source details

Original title: Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections: Results from a matched case-control study

Maria Helde-Frankling; Jonas Höijer; Jenny Bergqvist; Linda Björkhem-Bergman

PLoS ONE · 2017

Competing Interests: The authors have declared that no competing interests exist.

  • Conceptualization: LBB.

  • Data curation: MHF LBB.

  • Formal analysis: MHF JH JB LBB.

  • Funding acquisition: LBB.

  • Investigation: MHF JH JB LBB.

  • Methodology: MHF JH JB LBB.

  • Project administration: MHF LBB.

  • Resources: MHF JH JB LBB.

  • Software: MHF JH LBB.

  • Supervision: LBB.

  • Validation: MHF JH JB LBB.

  • Visualization: MHF JH LBB.

  • Writing: original draft: MHF LBB.

  • Writing: review & editing: MHF JH JB LBB.

* E-mail: linda.bjorkhem-bergman@ki.se
© 2017 Helde-Frankling et al2017Helde-Frankling et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/501100002794Cancerfondenhttp://orcid.org/0000-0003-3505-9283Björkhem-Bergman Linda http://dx.doi.org/10.13039/501100004348Stockholms Läns Landstinghttp://orcid.org/0000-0003-3505-9283Björkhem-Bergman Linda Financial support was provided through the Regional agreement on training and clinical research (ALF) between Karolinska Institutet and Stockholm County Council, The Swedish Cancer Society and Karolinska Institutet.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T22:56:41.976904+00:00

DOI: 10.1371/journal.pone.0184208 · PMC5578640